1. Antonia, S.J., et al., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med, 2017. 377(20): p. 1919-1929. 2. Antonia, S.J., et al., Overall Survival with Durvalumab after Che...
来源: [1]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-limited-stage-small-cell-lung-cancer [2]https://www.onclive.com/view/fda-approves-durvalumab-for-limited-stage-small-cell-lung-...
我们期待Durvalumab能给局部晚期的NSCLC患者带来治愈的希望。 参考来源:1. Antonia, S.J., et al., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med, 2017. 377(20): p. 1919-1929. 2. Antonia, S.J., et al., Overall Survival with Durvalumab after Chem...
Durvalumab after chemoradiotherapy in stage III non-small-cell lung can- cer. N Engl J Med 2017;377:1919-1929.Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J...
7. Paz-Ares L, Spira A, Raben D, et al: Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol 31:798-806, 2020 声明:本资料中涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见或指导。
参考来源:‘ FDA approves durvalumab for limited-stage small cell lung cancer. News release. FDA. December 4, 2024. Accessed December 4, 2024.’ 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。 编辑于 2024-12-05 10:57・IP 属地中国香港 ...
7. Paz-Ares L, Spira A, Raben D, et al: Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol 31:798-806, 2020 声明:本资料中涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见或指导。
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Background:Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study comp...
尽管整体的副作用Durvalumab组偏高,但是3/4级副作用发生率相当(29.9% vs 26.1%)。总的来说,Durvalumab组的无进展生存期显著长于安慰剂组,次级终点也支持Durvalumab组,两组间安全性相当。 Durvalumab after Chemo-radiotherapy in Stage III Non-Small-Cell Lung Cancer...
Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Durvalumab after Chemoradiotherapy: PACIFIC-KR (J Thorac Oncol; IF:20.121) Corresponding Author: In-Jae Oh, MD, PhD. Department of Internal Medicine, Chonnam National University Medical School...